{"disease":{"id":"mrd-positive","name":"mrd positive"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT07441291","title":"CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05940961","title":"Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Sheng-Li Xue, MD","has_results":false},{"nct_id":"NCT03919526","title":"Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT02992964","title":"Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"The Hospital for Sick Children","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}